Alvotech (ICE:ALVO)
| Market Cap | 312.71B |
| Revenue (ttm) | 68.10B |
| Net Income (ttm) | 7.67B |
| Shares Out | n/a |
| EPS (ttm) | 26.33 |
| PE Ratio | 40.77 |
| Forward PE | 18.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 530,621 |
| Average Volume | 146,378 |
| Open | 1,015.00 |
| Previous Close | 1,020.00 |
| Day's Range | 1,000.00 - 1,020.00 |
| 52-Week Range | 946.00 - 1,945.00 |
| Beta | 0.10 |
| RSI | 49.88 |
| Earnings Date | Nov 12, 2025 |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]
Full Company ProfileFinancial Performance
In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.
Financial numbers in USD Financial StatementsNews
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce...
Alvotech: Promising Vertically Integrated Biosimilar Platform
Alvotech is a vertically integrated biosimilar pure-play. In my view, this makes it a relatively safer bet compared to other, more speculative biotechs. ALVO plans on launching adalimumab and ustekinu...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, a...
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...
Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Alvotech (NASDAQ:ALVO) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Balaji Prasad - Chief Strategy Officer Conference Call Participants...
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today it...
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide a...
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce...
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today t...
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, a...
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced ...
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
REYKJAVIK, ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wo...